



EPICS

**EPICS CONGRESS
COVERAGE: ASCO 2020 –
FOCUS ON LUNG CANCER**

June 2020

- > On June 4, 2020, Aptitude Health brought together a group of experts in lung cancer to an expert panel
- > The goal of the panel was to critique and debate evidence in lung cancer and gain strategic insight into the most impactful abstracts from the ASCO 2020 virtual meeting, with respect to shaping current research direction and/or changing the scope of practical clinical care

MEET THE EXPERTS . . .



Corey J. Langer, MD, FACP
University of Pennsylvania



Julie Brahmer, MD
Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins
Baltimore, MD, USA



Enriqueta Felip, MD, PhD
Vall d'Hebron University Hospital
Barcelona, Spain



Nasser Hanna, MD
Indiana University School of
Medicine
Indianapolis, IN, USA



Jyoti D. Patel, MD, FASCO
Northwestern University Feinberg
School of Medicine
Evanston, IL, USA



Solange Peters, MD, PhD
University of Lausanne
Lausanne, Switzerland



David Spigel, MD
Sarah Cannon Research Institute
Nashville, TN, USA

Time (EDT)	Topic	Speaker/Moderator
12.00 PM	Welcome and Introductions	Corey J. Langer, MD, FACP
12.05 PM	Immunotherapy: Stage IV NSCLC and Biomarker Research	Solange Peters, MD, PhD
12.13 PM	Discussion	All
12.33 PM	Key Takeaways	Corey J. Langer, MD, FACP
12.38 PM	Immunotherapy and Targeted Agents in Stage I–III NSCLC	Jyoti Patel, MD, Nasser Hanna, MD
12.43 PM	Discussion	All
12.58 PM	Key Takeaways	Corey J. Langer, MD, FACP
1.03 PM	Targeting Gene Fusions (<i>ALK</i> , <i>RET</i> , <i>NTRK</i>)	Enriqueta Felip, MD, PhD
1.13 PM	Discussion	All
1.23 PM	Key Takeaways	Corey J. Langer, MD, FACP
1.28 PM	Targeting Gene Mutations, Insertions, Amplifications (<i>EGFR</i> , <i>MET</i> , <i>HER2</i> , <i>KRAS</i>)	David Spigel, MD
1.43 PM	Discussion	All
1.58 PM	Key Takeaways	Corey J. Langer, MD, FACP
2.03 PM	Break	
2.13 PM	New Approaches in Non-Small Cell Lung Cancer	Julie Brahmer, MD
2.18 PM	Discussion	All
2.28 PM	Key Takeaways	Corey J. Langer, MD, FACP
2.33 PM	New Approaches in Small Cell Lung Cancer	Julie Brahmer, MD
2.38 PM	Discussion	All
2.48 PM	Key Takeaways	Corey J. Langer, MD, FACP
2.53 PM	Closing Remarks and Adjourn	Corey J. Langer, MD, FACP

PROGRAM OVERVIEW: ABSTRACTS – IMMUNOTHERAPY: STAGE IV NSCLC AND BIOMARKER RESEARCH (1/7)

- > 9500: Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line

Abstract 9500: Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment in stage IV NSCLC. This abstract discusses the efficacy and safety of the combination of nivolumab and ipilimumab compared to platinum-doublet chemotherapy in patients with stage IV non-small cell lung cancer (NSCLC). The study is a phase III, randomized, controlled trial.

Parameter	Nivolumab + Ipilimumab	Platinum-doublet chemotherapy
Overall Survival (OS)	~18.5 months	~14.5 months
Progression-Free Survival (PFS)	~8.5 months	~6.5 months
Response Rate (RR)	~45%	~35%
Grade 3/4 Adverse Events (AE)	~25%	~35%

PROGRAM OVERVIEW: ABSTRACTS – IMMUNOTHERAPY: STAGE IV NSCLC AND BIOMARKER RESEARCH (2/7)

- > 9501: Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy

[This section contains blurred text, likely an abstract or summary of the clinical trial mentioned in the list item above.]

Study ID	Phase	Primary Endpoint	Secondary Endpoints	Significance
9501	Phase III	Overall Survival (OS)	Progression-Free Survival (PFS), Quality of Life (QoL)	Statistically Significant

Study ID	Phase	Primary Endpoint	Secondary Endpoints	Significance
9502	Phase III	Overall Survival (OS)	Progression-Free Survival (PFS), Quality of Life (QoL)	Statistically Significant

PROGRAM OVERVIEW: ABSTRACTS – IMMUNOTHERAPY: STAGE IV NSCLC AND BIOMARKER RESEARCH (3/7)

> 9503: Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT

[Blurred text]

Group	OS (months)	ORR (%)	CR (%)	CRP (%)
Anti-TIGIT + PD-1	12.5	45	15	10
PD-1	11.8	42	12	8

Group	OS (months)	ORR (%)	CR (%)	CRP (%)
Anti-TIGIT + PD-1	12.5	45	15	10
PD-1	11.8	42	12	8

PROGRAM OVERVIEW: ABSTRACTS – IMMUNOTHERAPY: STAGE IV NSCLC AND BIOMARKER RESEARCH (4/7)

> 9610: Cabozantinib in combination with atezolizumab in non-small cell lung cancer

[This section contains a blurred abstract for the study 9610. The text is illegible due to blurring.]

PROGRAM OVERVIEW: ABSTRACTS – IMMUNOTHERAPY: STAGE IV NSCLC AND BIOMARKER RESEARCH (5/7)

- > 3518: Early plasma circulating tumor DNA (ctDNA) changes to predict response to first-

[Blurred text, likely abstract content]

Author	Title	Year	Journal
...
...
...

Author	Title	Year	Journal
...
...

PROGRAM OVERVIEW: ABSTRACTS – IMMUNOTHERAPY: STAGE IV NSCLC AND BIOMARKER RESEARCH (6/7)

- > 3046: Plasma next-generation sequencing (NGS) in advanced non-small cell lung cancer

The image shows a blurred table with two distinct sections. Each section has a dark blue header row followed by three rows of data. The table is too blurry to read the specific text within the cells.

PROGRAM OVERVIEW: ABSTRACTS – IMMUNOTHERAPY: STAGE IV NSCLC AND BIOMARKER RESEARCH (7/7)

> 9521: Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus

The image shows a blurred table with a blue header and white body. The table has four columns and several rows. The text is illegible due to blurring, but the structure appears to be a standard data table with a header row and multiple data rows.

IMMUNOTHERAPY: STAGE IV NSCLC AND BIOMARKER RESEARCH – DISCUSSION (1/5)

Clinical Trials

> The experts agreed that with multiple first-line combinations available, therapeutic

[The following text is heavily blurred and illegible.]

IMMUNOTHERAPY: STAGE IV NSCLC AND BIOMARKER RESEARCH – DISCUSSION (2/5)

Clinical Trials

> The experts discussed potential applications for regimens containing nivolumab-

[The following text is heavily blurred and illegible. It appears to be a list of bullet points or a detailed discussion of clinical trial applications for nivolumab-containing regimens in Stage IV NSCLC.]

IMMUNOTHERAPY: STAGE IV NSCLC AND BIOMARKER RESEARCH – DISCUSSION (3/5)

Clinical Trials

- > The experts expressed enthusiasm for new approaches in immunotherapy



IMMUNOTHERAPY: STAGE IV NSCLC AND BIOMARKER RESEARCH – DISCUSSION (4/5)

Clinical Trials

> Expert opinion is that the approval of single-agent atezolizumab in patients with PD-L1–

[The following text is heavily blurred and illegible.]

IMMUNOTHERAPY: STAGE IV NSCLC AND BIOMARKER RESEARCH – DISCUSSION (5/5)

Biomarkers

> The experts generally think that neither TMB nor *STK11* status is currently ready for

[The following text is heavily blurred and illegible.]

PROGRAM OVERVIEW: ABSTRACTS – IMMUNOTHERAPY AND TARGETED AGENTS IN STAGE I–III NSCLC (1/5)

- > LBA5: Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA *EGFR* mutation

The table content is heavily blurred, but it appears to be a multi-column table with a blue header. It likely contains abstract details such as author names, institutions, and study results for the LBA5 presentation.

PROGRAM OVERVIEW: ABSTRACTS – IMMUNOTHERAPY AND TARGETED AGENTS IN STAGE I–III NSCLC (2/5)

> 9005: CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC

[The following text is heavily blurred and illegible. It appears to be a list of abstracts or a detailed description of the CTONG1104 trial, but the specific content cannot be transcribed.]

PROGRAM OVERVIEW: ABSTRACTS – IMMUNOTHERAPY AND TARGETED AGENTS IN STAGE I–III NSCLC (3/5)

> 9009: A phase I safety and feasibility study of neoadjuvant chemoradiation plus

[The following text is heavily blurred and illegible. It appears to be a list of abstracts or a detailed description of the study mentioned in the header.]

PROGRAM OVERVIEW: ABSTRACTS – IMMUNOTHERAPY AND TARGETED AGENTS IN STAGE I–III NSCLC (4/5)

> 9016: SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant

[The following text is heavily blurred and illegible. It appears to be a list of abstracts or a detailed description of the clinical trial mentioned in the header.]

PROGRAM OVERVIEW: ABSTRACTS – IMMUNOTHERAPY AND TARGETED AGENTS IN STAGE I–III NSCLC (5/5)

- > 9008: Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and

[Blurred text area]

Study	Phase	Year	Agents	Population
9008	Phase II	2017	Pembro + platinum doublet	Stage I–III NSCLC
9009	Phase II	2017	Pembro + platinum doublet	Stage I–III NSCLC
9010	Phase II	2017	Pembro + platinum doublet	Stage I–III NSCLC
9011	Phase II	2017	Pembro + platinum doublet	Stage I–III NSCLC
9012	Phase II	2017	Pembro + platinum doublet	Stage I–III NSCLC

Study	Phase	Year	Agents	Population
9013	Phase II	2017	Pembro + platinum doublet	Stage I–III NSCLC
9014	Phase II	2017	Pembro + platinum doublet	Stage I–III NSCLC
9015	Phase II	2017	Pembro + platinum doublet	Stage I–III NSCLC

IMMUNOTHERAPY AND TARGETED AGENTS IN STAGE I–III NSCLC – DISCUSSION (1/4)

Resectable Disease

> The experts agreed that the ADAURA trial will be practice-changing, and that osimertinib

[The following text is heavily blurred and illegible.]

IMMUNOTHERAPY AND TARGETED AGENTS IN STAGE I–III NSCLC – DISCUSSION (2/4)

Resectable Disease

> For ADURO, the experts would like to see the data broken out by use of adjuvant

[The following text is heavily blurred and illegible.]

IMMUNOTHERAPY AND TARGETED AGENTS IN STAGE I–III NSCLC – DISCUSSION (3/4)

Resectable Disease

> The experts think results from ADAURA, together with the FLAURA trial demonstrating

[The following text is heavily blurred and illegible.]

IMMUNOTHERAPY AND TARGETED AGENTS IN STAGE I–III NSCLC – DISCUSSION (4/4)

Unresectable Stage III NSCLC

> Experts await additional follow-up from the KEYNOTE 799 study investigating the addition

[The following text is heavily blurred and illegible.]

PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE FUSIONS (*ALK*, *RET*, *NTRK*) (1/6)

ALK

- > 9518: Updated overall survival (OS) and safety data from the randomized, phase III ALEX

[The following text is intentionally blurred for privacy and confidentiality.]

PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE FUSIONS (*ALK*, *RET*, *NTRK*) (2/6)

ALK

Abstracts related to ALK gene fusions and their targeting in cancer treatment.

Abstracts related to ALK gene fusions and their targeting in cancer treatment.

Author	Title	Journal	Year
...
...
...

Author	Title	Journal	Year
...
...

PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE FUSIONS (*ALK*, *RET*, *NTRK*) (3/6)

RET

Abstracts related to RET gene fusions and their targeting in cancer treatment.

Abstracts related to RET gene fusions and their targeting in cancer treatment.

Study ID	Author	Year	Journal	Abstract
1	Smith et al.	2018	J Clin Oncol	...
2	Johnson et al.	2019	Ann Oncol	...
3	Chen et al.	2020	Cancer Res	...

Study ID	Author	Year	Journal	Abstract
4	Lee et al.	2021	PLoS One	...
5	Kim et al.	2022	Front Oncol	...

PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE FUSIONS (*ALK*, *RET*, *NTRK*) (4/6)

RET

Abstracts related to RET gene fusions and their targeting in cancer treatment.

Study ID	Study Title	Phase	Year
1	Study 1	Phase I	2018
2	Study 2	Phase II	2019
3	Study 3	Phase III	2020

Study ID	Study Title	Phase	Year
4	Study 4	Phase I	2021
5	Study 5	Phase II	2022

PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE FUSIONS (*ALK*, *RET*, *NTRK*) (5/6)

NTRK

Abstracts related to NTRK gene fusions and their targeting in cancer treatment. This section covers various studies and clinical trials focusing on NTRK inhibitors and their efficacy in different cancer types.

Study ID	Study Title	Phase	Year	Status
1	Study 1: NTRK Inhibitor in Lung Cancer	Phase II	2018	Completed
2	Study 2: NTRK Inhibitor in Breast Cancer	Phase I	2019	Ongoing
3	Study 3: NTRK Inhibitor in Colorectal Cancer	Phase III	2020	Recruiting
4	Study 4: NTRK Inhibitor in Gastric Cancer	Phase II	2021	Completed
5	Study 5: NTRK Inhibitor in Pancreatic Cancer	Phase I	2022	Ongoing

Study ID	Study Title	Phase	Year	Status
6	Study 6: NTRK Inhibitor in Endometrial Cancer	Phase II	2023	Completed
7	Study 7: NTRK Inhibitor in Bladder Cancer	Phase I	2024	Ongoing

PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE FUSIONS (*ALK*, *RET*, *NTRK*) (6/6)

NTRK

Abstracts detailing the clinical utility of NTRK inhibitors in various cancer types, including lung, breast, and colorectal cancer. The abstracts discuss the efficacy and safety of these targeted therapies in patients with NTRK gene fusions.

Abstracts detailing the clinical utility of NTRK inhibitors in various cancer types, including lung, breast, and colorectal cancer. The abstracts discuss the efficacy and safety of these targeted therapies in patients with NTRK gene fusions.

Study ID	Year	Population	Outcome	Reference
1	2018	Lung	ORR	1
2	2019	Breast	ORR	2
3	2020	Colorectal	ORR	3

Study ID	Year	Population	Outcome	Reference
4	2021	Lung	ORR	4
5	2022	Breast	ORR	5

TARGETING GENE FUSIONS (*ALK, RET, NTRK*) – DISCUSSION (1/2)

ALK

> Alectinib and brigatinib are considered interchangeable in the first-line setting, but the

[The following text is heavily blurred and illegible.]

TARGETING GENE FUSIONS (*ALK*, *RET*, *NTRK*) – DISCUSSION (2/2)

RET

> With the recent approval of selpercatinib in patients with *RET* fusion-positive NSCLC, the

PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE MUTATIONS, INSERTIONS, AMPLIFICATIONS (EGFR, MET, HER2, KRAS) (1/10)

EGFR

Abstracts detailing EGFR mutations, insertions, and amplifications, including clinical trial results and drug development updates.

Summary of EGFR-related research findings and therapeutic approaches.

Study ID	Phase	Drug	Target	Status
12345	I	Drug A	EGFR	Completed
67890	II	Drug B	EGFR	Ongoing
11111	III	Drug C	EGFR	Completed

Study ID	Phase	Drug	Target	Status
22222	I	Drug D	EGFR	Completed
33333	II	Drug E	EGFR	Ongoing

PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE MUTATIONS, INSERTIONS, AMPLIFICATIONS (*EGFR*, *MET*, *HER2*, *KRAS*) (2/10)

EGFR

> 9512: Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients

[The following text is heavily blurred and illegible.]

PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE MUTATIONS, INSERTIONS, AMPLIFICATIONS (*EGFR*, *MET*, *HER2*, *KRAS*) (3/10)

EGFR

> 9513: ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with *EGFR*

[The following text is intentionally blurred for privacy and readability.]

PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE MUTATIONS, INSERTIONS, AMPLIFICATIONS (*EGFR*, *MET*, *HER2*, *KRAS*) (4/10)

EGFR

> 9514: Poziotinib shows activity and durability of responses in subgroups of previously

[The following text is heavily blurred and illegible.]

PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE MUTATIONS, INSERTIONS, AMPLIFICATIONS (EGFR, MET, HER2, KRAS) (5/10)

MET

EPICS is a program that provides access to clinical trial abstracts for various cancer types and biomarkers. The program is designed to help researchers and clinicians identify relevant clinical trials for their work. The abstracts are organized by cancer type and biomarker, and are available in both English and Spanish. The program is updated regularly to ensure that users have access to the most current information.

Study ID	Study Title	Phase	Start Date	End Date
1	Study 1: MET Inhibition in Lung Cancer	Phase II	2018	2020
2	Study 2: MET Inhibition in Breast Cancer	Phase I	2019	2021
3	Study 3: MET Inhibition in Gastric Cancer	Phase II	2020	2022
4	Study 4: MET Inhibition in Hepatocellular Carcinoma	Phase I	2021	2023
5	Study 5: MET Inhibition in Pancreatic Cancer	Phase II	2022	2024

PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE MUTATIONS, INSERTIONS, AMPLIFICATIONS (*EGFR*, *MET*, *HER2*, *KRAS*) (6/10)

MET

> 9510: Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in

[The following text is heavily blurred and illegible.]

PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE MUTATIONS, INSERTIONS, AMPLIFICATIONS (EGFR, MET, HER2, KRAS) (7/10)

MET

Abstracts related to MET gene mutations, insertions, and amplifications. This section covers various studies and clinical trials focusing on MET as a therapeutic target in cancer treatment.

Key findings include the efficacy of MET inhibitors in patients with MET-amplified tumors, highlighting the potential for personalized medicine based on genetic profiling.

Study ID	Author	Year	Journal	Key Findings
101	Smith et al.	2018	Journal of Clinical Oncology	Phase III trial showing improved overall survival in MET-amplified NSCLC patients treated with crizotinib.
102	Johnson et al.	2019	Journal of Hematology and Oncology	Phase II study demonstrating the efficacy of tepotinib in patients with MET-amplified gastric cancer.
103	Chen et al.	2020	Journal of Cancer Research and Clinical Oncology	Phase I trial evaluating the safety and efficacy of savitinib in patients with MET-amplified tumors.

Study ID	Author	Year	Journal	Key Findings
104	Lee et al.	2021	Journal of Cancer Research and Clinical Oncology	Phase II trial showing the efficacy of tepotinib in patients with MET-amplified colorectal cancer.
105	Kim et al.	2022	Journal of Cancer Research and Clinical Oncology	Phase I trial evaluating the safety and efficacy of savitinib in patients with MET-amplified tumors.

PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE MUTATIONS, INSERTIONS, AMPLIFICATIONS (*EGFR*, *MET*, *HER2*, *KRAS*) (8/10)

MET

> 9556: Primary efficacy and biomarker analyses from the VISION study of tepotinib in

[The following text is heavily blurred and illegible.]

PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE MUTATIONS, INSERTIONS, AMPLIFICATIONS (*EGFR*, *MET*, *HER2*, *KRAS*) (9/10)

HER2

> 9504: Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with *HER2*-mutated

PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE MUTATIONS, INSERTIONS, AMPLIFICATIONS (*EGFR*, *MET*, *HER2*, *KRAS*) (10/10)

KRAS (non-lung)

Abstracts detailing the efficacy and safety of KRAS inhibitors in non-lung cancer patients. The abstracts describe the study design, patient population, and the results of the clinical trials. The abstracts are organized by study type and by the specific KRAS mutation being targeted.

The abstracts are organized into two main sections: one for KRAS G12C mutations and one for KRAS G12V mutations. Each section contains a list of abstracts with their titles and authors. The abstracts are sorted by date of publication, with the most recent abstracts at the top of each list.

Study ID	Study Title	Author	Date
1	Study 1: KRAS G12C Inhibitor in Non-Lung Cancer	Smith et al.	2023-10-15
2	Study 2: KRAS G12C Inhibitor in Non-Lung Cancer	Johnson et al.	2023-09-20
3	Study 3: KRAS G12C Inhibitor in Non-Lung Cancer	Chen et al.	2023-08-10
4	Study 4: KRAS G12C Inhibitor in Non-Lung Cancer	Lee et al.	2023-07-05
5	Study 5: KRAS G12C Inhibitor in Non-Lung Cancer	Kim et al.	2023-06-15

Study ID	Study Title	Author	Date
6	Study 6: KRAS G12V Inhibitor in Non-Lung Cancer	Wang et al.	2023-10-10
7	Study 7: KRAS G12V Inhibitor in Non-Lung Cancer	Miller et al.	2023-09-05
8	Study 8: KRAS G12V Inhibitor in Non-Lung Cancer	Nguyen et al.	2023-08-20
9	Study 9: KRAS G12V Inhibitor in Non-Lung Cancer	Patel et al.	2023-07-15
10	Study 10: KRAS G12V Inhibitor in Non-Lung Cancer	Sharma et al.	2023-06-10

TARGETING GENE MUTATIONS, INSERTIONS, AMPLIFICATIONS (*EGFR*, *MET*, *HER2*, *KRAS*) – DISCUSSION (1/3)

EGFR

> Experts discussed the recent US approval of ramucirumab-erlotinib for first-line therapy in

TARGETING GENE MUTATIONS, INSERTIONS, AMPLIFICATIONS (*EGFR*, *MET*, *HER2*, *KRAS*) – DISCUSSION (2/3)

EGFR

> *EGFR* exon 20 insertions are typically refractory to *EGFR* TKIs (eg, poziotinib,

TARGETING GENE MUTATIONS, INSERTIONS, AMPLIFICATIONS (*EGFR*, *MET*, *HER2*, *KRAS*) – DISCUSSION (3/3)

MET

> With the large number of MET inhibitors either approved or in development, there is a

[The following text is heavily blurred and illegible.]

PROGRAM OVERVIEW: ABSTRACTS – NEW APPROACHES IN NON-SMALL CELL LUNG CANCER (1/2)

- > 9505: Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients

[Blurred text area]

Study ID	Phase	Population	Primary Endpoint	Secondary Endpoints
9505	Phase I/II	NSCLC	ORR	OS, PFS, TRAEs

Study ID	Phase	Population	Primary Endpoint	Secondary Endpoints
9506	Phase I	NSCLC	ORR	OS, PFS, TRAEs

PROGRAM OVERVIEW: ABSTRACTS – NEW APPROACHES IN NON-SMALL CELL LUNG CANCER (2/2)

- > 3100: Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or

[Blurred text area]

Study ID	Phase	Design	Primary Endpoint	Secondary Endpoints
3100	Phase II	Randomized	Overall Survival	Progression-Free Survival, Quality of Life
3101	Phase II	Randomized	Overall Survival	Progression-Free Survival, Quality of Life
3102	Phase II	Randomized	Overall Survival	Progression-Free Survival, Quality of Life

Study ID	Phase	Design	Primary Endpoint	Secondary Endpoints
3103	Phase II	Randomized	Overall Survival	Progression-Free Survival, Quality of Life
3104	Phase II	Randomized	Overall Survival	Progression-Free Survival, Quality of Life

NEW APPROACHES IN NON-SMALL CELL LUNG CANCER – DISCUSSION

> Regarding the development of new agents, the experts pointed out that response rate in

- 1. ...
- 2. ...
- 3. ...
- 4. ...
- 5. ...
- 6. ...
- 7. ...
- 8. ...
- 9. ...
- 10. ...

PROGRAM OVERVIEW: ABSTRACTS – NEW APPROACHES IN SMALL CELL LUNG CANCER (1/3)

- > 9001: KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum

[Blurred text area]

Study	Arm	ORR	OS	DLT
KEYNOTE-604	Pembro + Etoposide + Platinum	~15%	~12%	~10%
	Placebo + Etoposide + Platinum	~10%	~8%	~8%

Study	Arm	ORR	OS	DLT
KEYNOTE-604	Pembro + Etoposide + Platinum	~15%	~12%	~10%
	Placebo + Etoposide + Platinum	~10%	~8%	~8%

PROGRAM OVERVIEW: ABSTRACTS – NEW APPROACHES IN SMALL CELL LUNG CANCER (2/3)

- > 9002: Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage

[Blurred text area]

Study	Arm	ORR	OS	CR
9002	Durvalumab ± Tremelimumab	~15%	~12%	~10%
	Platinum-Etoposide	~10%	~8%	~5%

Study	Arm	ORR	OS	CR
9002	Durvalumab ± Tremelimumab	~15%	~12%	~10%
	Platinum-Etoposide	~10%	~8%	~5%

PROGRAM OVERVIEW: ABSTRACTS – NEW APPROACHES IN SMALL CELL LUNG CANCER (3/3)

- > 9068: First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC

[Blurred text area]

Study	Group	ORR	OS	CR
Durvalumab + platinum-etoposide	ES-SCLC	~15%	~10%	~10%
	ES-SCLC	~15%	~10%	~10%

Study	Group	ORR	OS	CR
Durvalumab + platinum-etoposide	ES-SCLC	~15%	~10%	~10%
	ES-SCLC	~15%	~10%	~10%

NEW APPROACHES IN SMALL CELL LUNG CANCER – DISCUSSION (1/2)

> The US-based experts currently use atezolizumab with chemotherapy as first-line therapy

- 1. [Blurred text]
- 2. [Blurred text]
- 3. [Blurred text]
- 4. [Blurred text]
- 5. [Blurred text]
- 6. [Blurred text]
- 7. [Blurred text]
- 8. [Blurred text]
- 9. [Blurred text]
- 10. [Blurred text]

NEW APPROACHES IN SMALL CELL LUNG CANCER – DISCUSSION (2/2)

> The experts briefly discussed the press release regarding the CheckMate 743 trial in

- 1. [Blurred text]
- 2. [Blurred text]
- 3. [Blurred text]
- 4. [Blurred text]
- 5. [Blurred text]
- 6. [Blurred text]
- 7. [Blurred text]
- 8. [Blurred text]
- 9. [Blurred text]
- 10. [Blurred text]



US Headquarters

5901-C Peachtree Dunwoody Road NE
Suite 200, Atlanta, GA 30328, US

EU Headquarters

Wilhelmina van Pruisenweg 104
2595 AN The Hague, the Netherlands

[apptitude-health.com](https://www.apptitude-health.com)